INHIBIKASE THERAPEUTICS INC (IKT) Stock News
NASDAQ:IKT - Nasdaq - US45719W2052 - Common Stock
IKT Latest News and Analysis
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
-- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage...
Bargain Hunters Take Note: Insider Cluster-Buying At IKT
Thursday 10/24 Insider Buying Report: IKT, MAN
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily...
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
-- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and ATLANTA, Oct. ...
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024
IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Inhibikase Therapeutics (NASDAQ:IKT) just reported results for the second quart...
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
Company to host conference call on August 15, 2024 at 8:00 a.m. ET
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
Company to host conference call on August 15, 2024 at 8:00 a.m. ET...
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage...
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
Company expects to report trial results in 4Q24
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
Company expects to report trial results in 4Q24...
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE)...
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage...
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024
IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Inhibikase Therapeutics (NASDAQ:IKT) just reported results for the first quarte...
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET...
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage...
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension – ...
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage...